このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

PeptiDream マネジメント

マネジメント基準チェック /24

PeptiDream'sの CEO はPatrick Crawford Reidで、 Sep2017年に任命され、の在任期間は 6.83年です。は、会社の株式の3.28%を直接所有しており、その価値は¥ 10.58B 。経営陣と取締役会の平均在任期間はそれぞれ2.5年と8.8年です。

主要情報

Patrick Crawford Reid

最高経営責任者

n/a

報酬総額

CEO給与比率	n/a
CEO在任期間	6.8yrs
CEOの所有権	3.3%
経営陣の平均在職期間	2.5yrs
取締役会の平均在任期間	8.8yrs

経営陣の近況

Recent updates

PeptiDream Inc. (TSE:4587) Surges 27% Yet Its Low P/S Is No Reason For Excitement

Jun 30

News Flash: Analysts Just Made A Meaningful Upgrade To Their PeptiDream Inc. (TSE:4587) Forecasts

Jun 02

CEO報酬分析

PeptiDream の収益と比較して、Patrick Crawford Reid の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Mar 31 2024	n/a	n/a	JP¥2b
Dec 31 2023	n/a	n/a	JP¥3b
Sep 30 2023	n/a	n/a	JP¥11b
Jun 30 2023	n/a	n/a	JP¥8b
Mar 31 2023	n/a	n/a	JP¥8b
Dec 31 2022	JP¥180m	JP¥90m	JP¥8b

報酬と市場: Patrick Crawfordの総報酬がJP市場の同規模の企業と比較して妥当かどうかを判断するにはデータが不十分です。

報酬と収益: Patrick Crawfordの報酬と会社の業績を比較するにはデータが不十分です。

CEO（最高経営責任者

Patrick Crawford Reid (49 yo)

6.8yrs

在職期間

JP¥179,999,000

報酬

Dr. Patrick Crawford Reid, Ph.D. has been President of PeptiDream Inc. since September 2017 and serves as its CEO since January 2022. Dr. Reid served as Head of R&D and Senior Vice President at PeptiDream...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Patrick Crawford Reid	President	6.8yrs	JP¥180.00m	3.28% ¥ 10.7b
Kiyofumi Kaneshiro	CFO, Executive VP & Director	2.5yrs	JP¥180.00m	0.033% ¥ 108.4m
Keiichi Masuya	COO, Executive VP & Director	2.5yrs	JP¥180.00m	0.041% ¥ 133.5m
Christian Cunningham	Chief Scientific Officer	less than a year	データなし	データなし
Yuko Okimoto	IR & Public Relations Director	no data	データなし	データなし
Masato Murakami	Chief Medical Officer	no data	データなし	データなし

2.5yrs

平均在職期間

49yo

平均年齢

経験豊富な経営陣: 4587の経営陣は経験豊富であると考えられます ( 2.4年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Patrick Crawford Reid	President	15.9yrs	JP¥180.00m	3.28% ¥ 10.7b
Kiyofumi Kaneshiro	CFO, Executive VP & Director	2.5yrs	JP¥180.00m	0.033% ¥ 108.4m
Keiichi Masuya	COO, Executive VP & Director	9.5yrs	JP¥180.00m	0.041% ¥ 133.5m
Michio Sasaoka	Independent External Director	8.8yrs	データなし	0.15% ¥ 502.0m
Yukinori Hanafusa	Independent External Director	8.3yrs	データなし	データなし
Toshio Nagae	Independent External Director	8.8yrs	データなし	0.0059% ¥ 19.1m
Junko Utsunomiya	Independent External Director	3.3yrs	データなし	データなし

8.8yrs

平均在職期間

53yo

平均年齢

経験豊富なボード: 4587の取締役会は経験豊富であると考えられます ( 8.8年の平均在任期間)。

PeptiDream マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

Insufficient new directors

PeptiDream Inc., Annual General Meeting, Mar 27, 2024

PeptiDream Inc., Annual General Meeting, Mar 29, 2023

Less than half of directors are independent

Less than half of directors are independent

PeptiDream Inc., Annual General Meeting, Mar 24, 2022

Recent updates

Price target increased by 7.4% to JP¥3,060

PeptiDream Inc. (TSE:4587) Surges 27% Yet Its Low P/S Is No Reason For Excitement

National Cancer Center and PeptiDream Announces the First Dosing of Cu-PD-32766 in a patient with Clear Cell Renal Cell Carcinoma

PeptiDream Inc. to Report Q2, 2024 Results on Aug 08, 2024

News Flash: Analysts Just Made A Meaningful Upgrade To Their PeptiDream Inc. (TSE:4587) Forecasts

Consensus revenue estimates increase by 10%

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Consensus EPS estimates fall by 15%, revenue upgraded

PeptiDream Inc.'s (TSE:4587) 42% Price Boost Is Out Of Tune With Revenues

Is PeptiDream Inc. (TSE:4587) Trading At A 46% Discount?

Insufficient new directors

PeptiDream Inc.'s (TSE:4587) 25% Jump Shows Its Popularity With Investors

PeptiDream Inc. to Report Q1, 2024 Results on May 14, 2024

Consensus EPS estimates fall by 17%

Full year 2023 earnings: EPS and revenues miss analyst expectations

PeptiDream Inc., Annual General Meeting, Mar 27, 2024

Now 21% undervalued

Investor sentiment improves as stock rises 16%

PeptiDream Inc. to Report Fiscal Year 2023 Results on Feb 14, 2024

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Price target decreased by 8.0% to JP¥2,817

New minor risk - Share price stability

New major risk - Revenue and earnings growth

PeptiDream Inc. to Report Q3, 2023 Results on Nov 09, 2023

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

New major risk - Revenue and earnings growth

Investor sentiment improves as stock rises 21%

PeptiDream Inc. to Report Q2, 2023 Results on Aug 09, 2023

Consensus EPS estimates increase by 11%

First quarter 2023 earnings: EPS misses analyst expectations

PeptiDream Inc. Provides Consolidated Earnings Guidance for the Year Ending December 31, 2023

PeptiDream Inc. Provides Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2023

Full year 2022 earnings: EPS exceeds analyst expectations

PeptiDream Inc., Annual General Meeting, Mar 29, 2023

Consensus EPS estimates increase by 25%

PeptiDream Inc. to Report Q4, 2022 Results on Feb 14, 2023

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Less than half of directors are independent

PeptiDream Inc. Provides Earnings Guidance for the Fiscal Year Ending December 31, 2022

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

PeptiDream Inc. Provides Consolidated Revenue Guidance for the Fiscal Year Ending December 31, 2022

Second quarter 2022 earnings released: JP¥1.75 loss per share (vs JP¥2.59 profit in 2Q 2021)

Price target decreased to JP¥3,300

PeptiDream Inc. to Report Q3, 2022 Results on Nov 10, 2022

Investor sentiment deteriorated over the past week

Price target decreased to JP¥3,586

First quarter 2022 earnings released: JP¥6.39 loss per share (vs JP¥3.43 profit in 1Q 2021)

PeptiDream Inc. Provides Consolidated Revenue Guidance for the Fiscal Year Ending December 31, 2022

Less than half of directors are independent

PeptiDream Inc. to Report Q1, 2022 Results on May 12, 2022

Investor sentiment deteriorated over the past week

Full year 2021 earnings: Revenues in line with analyst expectations

PeptiDream Inc. Provides Earnings Guidance for the Fiscal Year Ending December 31, 2022

PeptiDream Inc., Annual General Meeting, Mar 24, 2022

Price target decreased to JP¥4,413

Price target decreased to JP¥5,038

Third quarter 2021 earnings released: EPS JP¥19.97 (vs JP¥29.81 in 3Q 2020)

PeptiDream Inc. (TSE:4587) signed an agreement to acquire Radiopharmaceutical business of FUJIFILM Toyama Chemical Co., Ltd. from Fujifilm Corporation for ¥30.5 billion.

Full year 2020 earnings released: EPS JP¥35.40 (vs JP¥7.80 loss in FY 2019)

Chairman of the Board Kiichi Kubota has left the company

PeptiDream Inc. to Report Q2, 2021 Results on Aug 05, 2021

PeptiDream Inc. Announces Licensing of Automated PDPS Platform to Ono Pharmaceutical Co., Ltd

New 90-day low: JP¥5,070

Full year 2020 earnings released

PeptiDream Inc. Announces the Resignation of Kiichi Kubota from the Board of Directors

New 90-day high: JP¥6,440

New 90-day high: JP¥5,990

Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) completed the acquisition of remaining 58% stake in Kleo Pharmaceuticals, Inc from PeptiDream Inc. (TSE:4587) and others.

Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) entered into a merger agreement to acquire the remaining 58% stake in Kleo Pharmaceuticals, Inc from PeptiDream Inc. (TSE:4587) and others.

マネジメント基準チェック /24